BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Böhm M, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, Mahfoud F, Lopez‐sendon J, Ponikowski P, Tavazzi L, Swedberg K, Komajda M. Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. Eur J Heart Fail 2016;18:672-83. [DOI: 10.1002/ejhf.493] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Severino P, D’amato A, Prosperi S, Dei Cas A, Mattioli AV, Cevese A, Novo G, Prat M, Pedrinelli R, Raddino R, Gallina S, Schena F, Poggesi C, Pagliaro P, Mancone M, Fedele F; on behalf of the Italian National Institute for Cardiovascular Research (INRC). Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity? JCM 2022;11:857. [DOI: 10.3390/jcm11030857] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
2 Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Böhm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol 2021;149:27-35. [PMID: 33757788 DOI: 10.1016/j.amjcard.2021.03.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:872-81. [PMID: 33932268 DOI: 10.1002/ejhf.2206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lainscak M, Omersa D, Rosano G, Farkas J, Böhm M. Pharmacotherapy adherence in patients with heart failure: Easier said than done. Int J Cardiol 2021;332:135-7. [PMID: 33785392 DOI: 10.1016/j.ijcard.2021.03.051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Benstoem C, Kalvelage C, Breuer T, Heussen N, Marx G, Stoppe C, Brandenburg V. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev 2020;11:CD013004. [PMID: 33147368 DOI: 10.1002/14651858.CD013004.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lauder L, Ewen S, Kunz M, Richter LHJ, Jacobs CM, Kindermann I, Böhm M, Meyer MR, Mahfoud F. Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. J Am Heart Assoc 2020;9:e014180. [PMID: 32633188 DOI: 10.1161/JAHA.119.014180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Simpson J, Jackson CE, Haig C, Jhund PS, Tomaszewski M, Gardner RS, Tsorlalis Y, Petrie MC, McMurray JJV, Squire IB, Gupta P. Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. Eur Heart J Cardiovasc Pharmacother 2021;7:296-301. [PMID: 32597982 DOI: 10.1093/ehjcvp/pvaa071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sivakumar B, Malta D, Mak S, Dash S, Newton GE, Arcand J. Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure. Nutr Metab Cardiovasc Dis 2020;30:1005-13. [PMID: 32265100 DOI: 10.1016/j.numecd.2020.02.010] [Reference Citation Analysis]
9 Dinatolo E, Sciatti E, Anker MS, Lombardi C, Dasseni N, Metra M. Updates in heart failure: what last year brought to us. ESC Heart Fail 2018;5:989-1007. [PMID: 30570225 DOI: 10.1002/ehf2.12385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Katzmann JL, Mahfoud F, Böhm M, Schulz M, Laufs U. Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Prefer Adherence 2019;13:9-19. [PMID: 30587940 DOI: 10.2147/PPA.S182765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Patel HC, Kaye DM. Exercise training in heart failure: a long way to go yet. Eur J Heart Fail 2018;20:1744-5. [DOI: 10.1002/ejhf.1332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Cotter G, Davison BA. Unmodifiable events, heart failure research, and ‘risk‐based monitoring’ in large studies—the unholy triumvirate. Eur J Heart Fail 2018;20:1639-44. [DOI: 10.1002/ejhf.1282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Laufs U, Griese-Mammen N, Krueger K, Wachter A, Anker SD, Koehler F, Rettig-Ewen V, Botermann L, Strauch D, Trenk D, Böhm M, Schulz M. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. Eur J Heart Fail 2018;20:1350-9. [PMID: 29846031 DOI: 10.1002/ejhf.1213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
14 Ferrari R, Bueno H, Chioncel O, Cleland JG, Stough WG, Lettino M, Metra M, Parissis JT, Pinto F, Ponikowski P, Ruschitzka F, Tavazzi L. Acute heart failure: lessons learned, roads ahead: Viewpoint. Eur J Heart Fail 2018;20:842-50. [DOI: 10.1002/ejhf.1169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
15 Metra M. June 2016 at a glance: epidemiology, renal impairment, heart failure with preserved ejection fraction. Eur J Heart Fail 2016;18:587. [PMID: 27324685 DOI: 10.1002/ejhf.602] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Oliva F, Sormani P, Contri R, Campana C, Carubelli V, Cirò A, Morandi F, Di Tano G, Mortara A, Senni M, Metra M, Ammirati E. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. International Journal of Cardiology 2018;253:97-104. [DOI: 10.1016/j.ijcard.2017.09.191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
17 Nikolovska Vukadinović A, Vukadinović D, Borer J, Cowie M, Komajda M, Lainscak M, Swedberg K, Böhm M. Heart rate and its reduction in chronic heart failure and beyond: Heart rate and its reduction in chronic heart failure and beyond. Eur J Heart Fail 2017;19:1230-41. [DOI: 10.1002/ejhf.902] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]